Pathos AI has secured $365 million in Series D financing, pushing its post-money valuation to approximately $1.6 billion. This latest funding round follows a $62 million Series C round led by New Enterprise Associates just seven months ago, bringing the AI-driven biotech company's total funding to around $467 million.

The substantial investment will fuel the advancement of Pathos AI's clinical-stage drug pipeline and support ongoing development of their oncology-specific AI foundation model. Though the company has not disclosed the participants in this latest financing round, the significant capital injection demonstrates strong investor confidence in their approach.

"With this financing, we're building one of the most advanced AI engines," said Iker Huerga in Thursday's announcement. Huerga, who was appointed CEO earlier this month after serving as chief data scientist for oncology R&D at AstraZeneca, brings valuable industry experience to the company's leadership.

At the core of Pathos AI's technology is what they describe as "the largest multimodal foundation model in oncology." Their platform, PathOS, integrates clinical, molecular, and imaging data to enhance asset selection, optimize clinical trial design, and identify novel biomarkers. The system has already proven its value by guiding the acquisition of two cancer drugs currently in clinical testing.

The company's lead asset, pocenbrodib (formerly FT-7051/P300), was licensed from Novo Nordisk in 2023. This drug targets CREBBP/EP300 proteins that activate genes promoting cancer cell growth and is currently in Phase I/II trials for metastatic castration-resistant prostate cancer. The study is evaluating pocenbrodib both as a monotherapy and in combination with established treatments including Johnson & Johnson's Zytiga, AstraZeneca and Merck's Lynparza, and Novartis's Pluvicto.

Pathos AI's second pipeline asset, P-500 (previously PRT811), is a brain-penetrant PRMT5 inhibitor acquired from Prelude Therapeutics last August. Now in mid-stage testing, the compound showed promising results in early trials, with two confirmed complete responses among 16 patients with IDH-mutated high-grade glioma.

"Proceeds from this round will enable us to significantly accelerate the development of both programmes and in-license new ones," Huerga told FirstWord in an email. "For both programmes, our near-term milestones include clinical trial initiation or expansion, initial readouts, and advancing biomarker-driven development strategies. Timelines vary by asset, but we expect meaningful progress over the next 12–24 months."

Click here for the original news story.